Biosynex has acquired Para’kito
April 2022 — Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.
Created in 2005, Biosynex is a leading public health player in France and Europe. The group develops, manufactures and markets medical devices for screening, diagnosis and prevention. Biosynex is the French market leader in the design and distribution of rapid tests (RDT), commercialized in 90+ countries. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, resellers and department stores. In 2021, the group generated over US$400 million of sales.
Launched in 2008, Para’kito is the leading European brand in the prevention and care of mosquito bites. The company provides a complete range of anti-mosquito bracelets and sprays based on 100% natural formulas, with a proprietary technology, and distributed via two channels: pharmacies and e-commerce. Para’kito is present in more than 30 countries and supplies 5,000+ pharmacies in France. In 2021, the brand generated over US$7 million of sales in Europe.
Our role in the transaction
Oaklins’ team in France acted as M&A advisor to Biosynex in this transaction.
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more